Gene expression profiling predicts response to temozolomide in malignant gliomas.

@article{Yoshino2010GeneEP,
  title={Gene expression profiling predicts response to temozolomide in malignant gliomas.},
  author={Atsuo Yoshino and Akiyoshi Ogino and Kazunari Yachi and Takashi Ohta and Takao Fukushima and Takao Watanabe and Yoichi Katayama and Yutaka Okamoto and Norio Naruse and Emiko Sano and Kouhei Tsumoto},
  journal={International journal of oncology},
  year={2010},
  volume={36 6},
  pages={1367-77}
}
Malignant gliomas are highly lethal neoplasms that cannot be cured with currently available therapies. Temozolomide (TMZ) is a recently introduced alkylating agent that has yielded significant benefits and become a key agent in the treatment of high-grade gliomas. However, its survival benefit remains unsatisfactory. Understanding the molecular basis of TMZ… CONTINUE READING